Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EP262 · 3 trials · 3 indications
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. A TEAE is defined as an adverse event (AE) with an onset after the first dose of study drug or an existing event that worsened after the first dose during the study.
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable or unintended sign (including a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. A TEAE is defined as an adverse event (AE) with an onset after the first dose of study drug or an existing event that worsened after the first dose during the study. AEs were graded for severity using the the Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v.5). CTCAE grades were scored as: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life threatening; Grade 5 = death related to the AE.
Clinical meaningfulness was determined by the investigator.
Clinical meaningfulness was determined by the investigator.
Clinical meaningfulness was determined by the investigator.
Assessed by the total recovery of radioactivity from urine and feces
Assessed by the concentration of EP262 in plasma and \[14C\] in whole blood, plasma, urine, and feces
Assessed by the incidence of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| EP262 150 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| [14C]-EP262 25 mg | EXPERIMENTAL | Administered orally. |
| Name | Type | Description |
|---|---|---|
| Oral EP262 | DRUG | Once daily |
| Placebo | DRUG | Once Daily |
| EP262 | DRUG | Single dose of \[14C\]-EP262 administered orally. |
Inclusion Criteria: * Clinically confirmed diagnosis of active atopic dermatitis for at least 1 year * BSA of 3% to 20% and a vIGA-AD score of ≥3 Exclusion Criteria: * Other active skin diseases associated with chronic pruritus * Clinically infected atopic dermatitis that requires antibiotic ther...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
EP262 is an investigational small molecule being developed by Incyte Corporation for chronic inducible urticaria and atopic dermatitis. It has been studied in clinical trials involving healthy participants, as well as patients with these dermatologic conditions.
EP262 is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY.
EP262 is in clinical development. It has completed Phase 1 and Phase 2 trials, including a Phase 2a study in atopic dermatitis. It is not FDA approved and remains investigational.
EP262 has been studied in three completed trials: NCT06050928 (Phase 1b in chronic inducible urticaria), NCT06144424 (Phase 2a in atopic dermatitis), and NCT06645704 (Phase 1 healthy volunteer study). All trials are completed.
No alternative names for EP262 have been identified. It is referred to solely as EP262 in clinical trial records and by its developer, Incyte Corporation.